Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Recruiting 3Available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2mCRPC 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Leukemia 1Extensive Stage Lung Small Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 15Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 12Ipilimumab 12Gemcitabine 10Radiosurgery 8Irinotecan 8abemaciclib 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6atezolizumab 6osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Docetaxel 5Cetuximab 5palbociclib 4Taxes 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × talazoparib × Clear all
NCT02286687 2026-06-12

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
150 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡